PMLiVE9d
Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type
Merck KGaA and Abbisko Therapeutics have announced positive results from a late-stage study of pimicotinib in patients with tenosynovial giant cell tumours (TGCTs). The phase 3 MANEUVER trial has been ...
PMLiVE10d
AstraZeneca/Merck’s Koselugo shows promise in adults with neurofibromatosis type 1
AstraZeneca (AZ) and Merck – known as MSD outside the US and Canada – have shared positive results from a late-stage study of Koselugo (selumetinib) in adults with neurofibromatosis type 1 (NF1), rare ...
PMLiVE10d
J&J’s nipocalimab granted FDA breakthrough designation for Sjögren’s disease
Johnson & Johnson (J&J) has announced that its anti-FcRn antibody nipocalimab has become the first investigational therapy to be granted breakthrough therapy designation (BTD) by the US Food and Drug ...